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Review
Physiological and Psychological Effects of Exercise
Interventions in HIV Disease
WESLEY D. DUDGEON, B.A.,1 KENNETH D. PHILLIPS, Ph.D., R.N.,2
CHRISTOPHER M. BOPP, M.S.,1 and GREGORY A. HAND, Ph.D.1

ABSTRACT
The use of both aerobic and resistance exercise has been shown to improve physiologic parameters such as strength, endurance, time to fatigue, and body composition in the HIV-infected population. Exercise has also been used successfully to treat psychologic conditions
such as depression and anxiety that are common in HIV-infected individuals. However, the
effects of exercise on immune function in these individuals are uncertain because of conflicting results found among studies. Additionally, many ventures into this area have been
attempted with poor research design, resulting in inconclusive evidence or poor generalizability. The focus of this paper is to review the research that has been performed using exercise as an intervention for HIV-infected persons and to determine what needs to be done
next to further our understanding of how the HIV-infected body and mind respond to exercise training.
infected individuals; a vaccine that effectively
prevents HIV infection is the ultimate goal.
Health care providers are beginning to prescribe nonpharmacologic complementary and
alternative therapies to prevent and manage
complications associated with HIV/AIDS. An
intriguing, nonpharmacologic treatment for
preventing and managing complications of
HIV infection is moderate intensity exercise
training.1–3 Moderate-intensity exercise training has been shown not only to be safe, but also
beneficial for increasing lean muscle mass, decreasing fat mass, and improving muscular
strength. Additionally, exercise has been shown

INTRODUCTION

T

resulting from HIV/
AIDS radically alter the physiologic and
psychological well-being of HIV-infected individuals. Treatment with highly active antiretroviral therapy (HAART) allows HIV-infected individuals to live longer, healthier, and
more productive lives than was possible at the
beginning of the HIV/AIDS pandemic. However, these life-extending antiretroviral medications often cause side effects that may adversely
affect quality of life. Medical researchers are continually seeking more effective methods to treat
HE
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to improve various mental health problems in
noninfected individuals, thus exercise is being
proposed to improve psychological parameters
in HIV-infected individuals.4,5 The purpose of
this paper is to identify physiologic and psychological alterations that result from HIV/
AIDS and to analyze what is known regarding
the effectiveness of exercise interventions in
preventing and managing these complications.
A literature search was conducted on the
MEDLINE database, with limits set for only
original data, using combinations of the keywords “exercise,” “HIV,” “AIDS,” and “physical activity.” This search produced 29 research
studies involving the use of exercise as an intervention for HIV-infected persons. Searching
without limits also produced 12 review articles
on this subject, as well as literature regarding
the functional limitations of HIV-infected individuals.
Physiologic alterations of HIV infection
HIV-infected persons face many metabolic
conditions that researchers have addressed
with therapeutic exercise. One such condition,
wasting syndrome, is recognized by involuntary weight loss of more than 10% baseline
body weight in addition to prolonged fever,
chronic weakness, and chronic diarrhea.6 The
significant loss of tissue present with the wasting syndrome increases the risk of mortality
and secondary infection.6
Lipodystrophy syndrome, a side effect of
HAART, is characterized by fat accumulation
in the abdomen and trunk with fat loss in the
legs, arms, and face.7,8 HAART can increase the
rate of lipid breakdown while decreasing the
rate of lipid synthesis, especially in the periphery.9 Furthermore, the elevation of circulating cytokine levels, such as tumor necrosis
factor (TNF)-a, that accompany HIV infection
can decrease lipoprotein lipase levels resulting
in a decrease in fat deposition. 9
Immune response to chronic fever and infection results in an elevation of circulating cytokines such as interleukin-1 (IL-1) and TNF-a.
Elevated levels of IL-1 and TNF-a can increase
resting energy expenditure, and TNF-a has additionally been associated with decreased
lipoprotein lipase activity, depletion of energy
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stores, and suppression of food intake.10 Increased circulating cytokines further influence
metabolic rates by activating the hypothalamicpituitary-adrenal axis (HPAA), which leads to
an increase in glucocorticoid levels. Increased
glucocorticoid levels have a catabolic influence
on skeletal muscle by slowing protein synthesis rate and increasing protein degradation.11
Increased rate of protein turnover and elevated metabolic rate caused by the combined
cytokine and glucocorticoid response can increase resting metabolic rates and lead to accelerated depletion of energy stores. During
periods of infection, when cytokine and glucocorticoid levels rise significantly, resting energy levels are further elevated and food intake
drops, thus causing accelerated and episodic
weight loss.12–14
HIV-infected individuals also suffer from a
high prevalence of anemia, with reports of up
to 28% prevalence.15 The increase in circulating
cytokines common with HIV-infection can inhibit the production of erythropoietin (EPO),
which may partly explain the low EPO levels
reported in HIV-infected individuals.16 Additionally, certain medications used in the treatment of HIV infection, including zidovudine
and trimethoprim-sulphamethoxazole, have
been linked to development of anemia.17
Psychological alterations of HIV infection
HIV-infected populations have higher incidences of psychiatric disorders than the uninfected population.18 The most notable psychological abnormalities include anxiety and
depression. Heckman and colleagues19 found
that 25% of people age 50 or older living with
HIV presented with moderate to severe levels
of depression. This is consistent with the 22%
to 45% prevalence rate of depression in HIVinfected persons as reported by Penzak and
others, 20 who also link depression to altered
course of infection due to impaired immune
function and nonadherence to therapy.
Depressed and anxious HIV-infected individuals present with decreased natural killer
cell activity, increased viral load, and elevated
CD81 T lymphocytes. 21 With the exception of
viral load levels, these are the typical immune
disorders associated with chronic stress.22 Sup-
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pression of immune function can be traced to
hypoactivity of glucocorticoid receptors on immune cells and in limbic regions of the brain.
This in turn may lead to increased secretion of
proinflammatory cytokines and augmented
HPAA activity.23 Thus, management of stress
is significant in treating the HIV-infected population, as increased levels of stress and depression have been associated with more rapid
progression to AIDS.24
Mental health problems are also important
to disease progression because of their negative effect on drug adherence. It has been found
that HIV-infected individuals suffering from
mental health disorders, regardless of the
severity, have poorer drug adherence.25,26
Specifically, depression has been directly linked
to nonadherence in HIV-infected persons.27–29
Nonadherence to therapy is a major concern
because nonadherence leads to faster disease
progression and to antiviral-resistant strains of
HIV.30–34
Aerobic training
The classification of aerobic as a method of
exercise refers to exercise that requires oxygen
to generate adenosine triphosphate (ATP) for
the functioning of skeletal muscle.35 Aerobic
metabolism of lipids occurs in the muscle mitochondria during b-oxidation, which involves
energy production from plasma free fatty acids
and intramuscular triglycerides. The b-oxidation cycle then feeds acetyl-CoA into the tricarboxcyclic acid (TCA) cycle, also located in
the mitochondria, where carbon dioxide (CO2)
and hydrogen (H1 ) ions are removed. The H1
ions are then passed down the electron transport chain where they are oxidized to produce
ATP. Additionally, glycolysis via the catabolism of blood glucose and/or muscle glycogen
can directly produce energy for the active muscle, as well as producing pyruvate which eventually reaches the TCA cycle in the form of
acetyl-CoA. 36 Exercise at a level of 3–6 METs (1
MET 5 the amount of energy expended during
1 minute of rest) or 50%–85% maximal oxygen
uptake (VO 2max), for 20 to 60 minutes, is generally prescribed to elicit aerobic conditioning.37 Other methods of prescription involve
training in a target heart rate zone, but because

of the occurrence of cardiac neuropathy in HIVinfected persons, 38 this prescription can be unreliable.
Current work to date in the prescription of
aerobic exercise for HIV-infected persons has
used stationary cycling and treadmill walking
as modes of conditioning. Typical prescription
has included work at 50%–85% VO 2 max or
60%–85% maximum heart rate, 3 times per
week for a duration ranging from 10–24 weeks.
Resistance training
Resistance training, or the overloading of
skeletal muscle, serves to increase muscular
strength and muscular endurance. These functional improvements are possible because
skeletal muscle adapts to load by increasing in
size, strengthening connective tissue, and improving bone density.35 Thus, muscle is better
able to perform when a stress is again introduced, and functional performance is enhanced. It should be noted, that adaptation of
muscle is specific to the type of training performed. In the reviewed literature progressive
resistance training has also been used as a
means of improving muscular strength and endurance. This type of programming aims at ensuring the appropriate training intensity by
continually increasing resistance as the muscle
adapts to the implemented load.37
Most resistance training is of short duration,
less than 60 seconds, thus anaerobic means of
ATP production are sufficient. Anaerobic energy production can be carried out by glycolysis, with lactic acid as the byproduct instead of
pyruvate. The creatine phosphate (CP) system,
in which adenosine diphosphate (ADP) and CP
together synthesize ATP, is also a method of
anaerobic ATP production.36
The reviewed work that has used resistance
training as an intervention for HIV infected populations shows a common type of program; 3
sessions per week for 8 weeks consisting of 3
sets of 8 repetitions on each exercise. Proper resistance is based on a 1-repetition maximum (1RM), preintervention effort on each exercise.
Other programs implement a progressive model
in which the number of repetition and sets remains constant, while the intensity of the exercise is increased at predetermined time points.
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Additional studies have combined aerobic
and resistance exercise into the same intervention. These programs usually last 12–16
weeks, and include 20 minutes of aerobic activity followed by 35 to 40 minutes of resistance training. Total workout time has usually
been limited to 1 to 1.5 hours and stretching
has periodically been included.
RESULTS
The immunologic and physiologic and psychologic effects of exercise are summarized in
Tables 1–3.
Physiologic and physiological effects of exercise
Exercise is known to produce many desirable
health benefits in apparently healthy populations. Studies have shown that regular exercise
reduces the risk of adult onset diabetes,39 hypertension,40 and coronary artery disease.41 Exercise is also beneficial to those with cancer and
arthritis, conditions that include wasting.42–44
Exercise has been shown to positively alter enzymatic activity and increase contractile protein mass, both effects that aid in combating
wasting.45,46
The literature regarding the effects of exercise on immune function, however, is ambiguous. The primary reason for this lack of cohesion is because of the various methods of data
collection that make comparing results nearly
impossible. The type of exercise prescribed,
whether it is aerobic or resistance, as well as
the intensity of the exercise (light, moderate,
heavy) is also a factor that makes determining
the overall effect of exercise on immune function difficult. Finally, it is absolutely necessary
to determine the criteria by which immune
function is measured, and whether that measure has any observable health consequence.
With this in mind, however, much information regarding the effects of exercise on immune function have been discovered. After exercise, there is a biphasic response of the
immune system in which circulating monocytes and lymphocytes decrease below resting
levels,47–49 while a rise in neutrophils is observed, even hours after exercise.50–53 A redistribution of lymphocytes occurs in which helper

T cells are decreased and natural killer (NK)
cell numbers are elevated,49,54 and the ratio of
T-helper to T-suppressor cells can decrease by
half.55,56
Functioning of these immune components
during and after exercise has been addressed.
Exercising within the American College of
Sports Medicine Guidelines (ACSM), 50%–85%
VO 2max, will cause a transient decrease in Tlymphocyte proliferation, 50,54,55,57 although no
studies have shown this as being detrimental
to health. Research has also not shown exercise
to alter the functioning of B-lymphocytes or immunoglobulin production in any way. What is
clear, however, is that exercise of less than 60
minutes in duration will cause a dose-dependent increase in NK cell function during and
immediately postexercise, but NK cell activity
can then be depressed for up to 180 minutes.58–60
Regular exercise can also be beneficial to psychological functioning.61 The use of aerobic exercise has been shown to reduce the severity of
depressive symptoms and improve mood. 62,63
Both aerobic and resistance exercise were also
found to decrease levels of anxiety over an 8week period.64
Efficacy of exercise in HIV-infected persons
Calabrese and LaPerriere65 found that exercise is safe and beneficial for HIV-infected persons. To be most beneficial, they recommend
beginning exercise before symptoms present
and also cite the potential of exercise to provide behavioral benefits. It has even been
shown that exercise after periods of acute infection is safe and beneficial for regaining
weight lost during the symptomatic period.2
While HIV-infected persons are encouraged
to participate in exercise, certain limitations do
exist. Many of these limitations are the result
of loss of lean body mass, decreased muscular
strength, or various metabolic changes that are
side effects of HAART.66 A common deficiency
directly affecting normal daily activities is maximal oxygen consumption, VO 2max (mL/kg/
min), a measure of functional capacity, which
was found to be “well below average” in adolescents seropositive for the HIV virus compared to age-matched, uninfected controls. 67

Males, 18–40
yrs old

Males and females,
21–46 yrs old

Males, 18–40
yrs old

Males and females,
27–45 yrs old

Males and females,
23–39 yrs old

Males

LaPerriere et al.,
1991

MacArthur et al.,
1993

LaPerriere et al.,
1994

Stringer et al.,
1998

Terry et al.,
1999

Mustafa et al.,
1999

HR, heart rate.

Males

Subjects

LaPerriere et al.,
1990

Author

TABLE 1.
OF

Total 156

Total 21:
Females (n 5 17)
High intensity (n 5 11)
Moderate intensity
(n 5 10)

Total 26:
Females (n 5 3)
Control (n 5 8)
Moderate (n 5 9)
Heavy (n 5 9)

Total 14:
Exercise (n 5 7)
Control (n 5 7)

Self-report of exercise 3–4 times per
week considered exercise and less
being nonexercisers

12 weeks of treadmill training at 60%
max HR (moderate) or 84% max
HR (high) 3 times a week for 30
minutes

6 weeks of training on stationary
bicycle at an increasing work rate
from 15–25 W/min until
exhaustion, with time adjusted so
each group produced the same
work, 3 times per week

24 weeks of cardiovascular exercise
at 50–60% VO 2 max for lowintensity group and 75–85% VO 2
max for high-intensity group, 3
times a week with a caloric
expenditure of 250, 350, and 500
k/cal per session for weeks 1–8,
9–16, and 17–24, respectively
10 weeks of training on stationary
bicycle at 70–80% max HR, 3 times
per week for 45 minutes per
session

5 weeks of interval training on
stationary bicycle at 70–80% max
HR, 3 times per week for 45
minutes a session

Results

significant change in
(170* mL vs. 190* mL)
significant change in
(185* mL vs. 195* mL)

Significant increases in:
CD21 (1717 vs. 2183 mm3)
CD41 (942 vs. 1280 mm3)
CD81 (655 vs. 816 mm3)
CD45RA1 CD41 (312 vs. 955 mm3)
CD201 (162 vs. 244 mm3)
Moderate: No significant changes in
CD41 count (297 vs. 310 mm3)
Moderate: No significant change in
viral load (56,101 vs. 45,698/mL)
Heavy: No significant changes in
CD41 count (342 vs. 339 mm3)
Heavy: No significant change in viral
load (11,706 vs. 10,326/mL)
No significant changes from baseline
at 6 or 12 weeks for:
CD41 cells (592 vs. 614 vs. 683 mm3)
CD81 cells (1030 vs. 1242 vs. 1252
mm3)
Leukocytes (6344 vs. 6400 vs. 6930
mm3)
Lymphocytes (2148 vs. 2627 vs. 2638
mm3)
Exercise group showed slower
progression to AIDS and slower
progression to death from AIDS as
well as increase in CD41 counts
each year

Week 12: No
CD41 cells
Week 24: No
CD41 cells

Control: 61 cells/mm3 decrease in
CD41 count
Exercise: 38 cells/mm3 increase in
CD41 count
Significant increase in exercise group
CD41 cells (904 vs. 1020 mm3)
CD45RA1 CD41 (no quantification
given)

HIV-INFECTION POPULATIONS

Intervention

IN

45-minutes of aerobic exercise on a
stationary bicycle at 80% age
predicted max HR

EXERCISE INTERVENTIONS

Total 39:
HIV 1 exercise (n 5 12)
HIV 1 controls (n 5 10)
HIV-exercise (n 5 11)
HIV-controls (n 5 6)
Total 32:
Females (n 5 2)
10 completed 12 wks,
6 completed 24 wks

Total 23:
Exercise (n 5 10)
Control (n 5 13)

Number

IMMUNOLOGIC OUTCOMES
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Males, 29–41
yrs old

Males

Males and females,
25–56 yrs old

Males and females,
23–39 yrs old

Males, 18–50
yrs old/w 5%
loss of BW

Males with AIDS
wasting

Wagner et al.,
1998

Roubenoff et al.,
1999

Terry et al.,
1999

Bhasin et al.,
2000

Grinspoon et al.,
2000

Subjects

Rigsby et al.,
1992

Author

TABLE 2.
OF

Total 21:
Females (n 5 17)
High-intensity
(n 5 11)
Moderate-intensity
(n 5 10)
Total 49:
Placebo (n 5 12)
Testosterone (n 5 15)
Exercise 1 placebo
(n 5 11),
Exercise 1
testosterone (n 5 11)
Total 43:
Placebo (n 5 12)
Placebo 1 exercise
(n 5 10),
Testosterone (n 5 10)
Testosterone 1
exercise (n 5 11)

Total 25:
Males (n 5 20)
Females (n 5 5)
With wasting (n 5 6)
Without wasting (n 5 19)

IN

3 exercise sessions per week for 16
weeks, weeks 1–4 60% 1-RM for
12–15 repetitions, weeks 5–10, 4
sets of 4–6 repetitions at 90% 1-RM
intensity on heavy days, 80% 1-RM
on medium days, and 70% 1-RM
on light days
3 exercise sessions per week for 12
weeks consisting of 20 minutes on
stationary bicycle at 60–70% age
predicted max HR, week 1 & 2, 2
sets 8 repetitions at 60% RM,
weeks 3–6, 2 sets 8 repetitions
70%, weeks 7–12, 3 sets 8
repetitions at 80%

12 weeks of treadmill training at 60%
max HR (moderate) or 84% max
HR (high) 3 times per week for 30
minutes

Exercised an average of 3.4 days per
week, for an average of 87
minutes, at an average intensity of
6.1 out of 8
3 sets of 8 repetitions for 8 weeks
with week 1 repetitions at 50%
RM, week 2 repetitions at 60%
RM, and week 3–8 at 75–80% RM

12 weeks for 3 days per week for 1
hour, 20 min cycling at 60–80%
max HR followed by 35 minutes of
strength and flexibility training

Results

Significant increase in strength with
exercise only (29–36%) and with
testosterone only (17–28%)
Significant increase in thigh muscle
volume in the testosterone only (40
cm3, (p , 0.001) and the exercise
only group (62 cm3, p 5 0.03)
Significant increase in LBM:
2.3 kg with training
4.2 kg with/training 1 testosterone

Significant (p , 0.0002) increase in
lean body mass (1.75 6 1.94 kg)
Significant percent increases in
strength (as tested by 1-RM) on
the:
Chest press (31 6 18%)
Leg press (40 6 23.6%)
Upper back (50 6 27%)
Quadriceps extension (38 6 31%).
Significant (p , 0.05) decrease in fat
mass (0.92 6 2.22 kg)
Functional capacity significantly
improved in moderate intensity
group 680 6 81 vs. 750 6 151s and
high intensity group 651 6 122 vs.
841 6 158s

Significant improvements in strength
for exercise group only:
Chest press (189.4 6 25.6 vs. 239.7 6
33.2 n?m)
Leg extension (158.7 6 43.4 vs. 206.3
6 43.1 n?m)
Total time completed during the
cycle test (996.15 6 170.43 vs.
1388.46 6 224.45 s)
Significant (p , 0.000) improvement
in lean body mass (61.6 6 7.2 vs.
64.2 6 8.2 kg) for exercise group

HIV-INFECTION POPULATIONS

Intervention

EXERCISE INTERVENTIONS

Total 29:
Resistance (n 5 10)
Cardiovascular (n 5 2)

Total 31:
Exercise (n 5 16)
Counseling (n 5 15)

Number

PHYSIOLOGIC EFFECTS
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Males with AIDS
wasting

Males and females

Males over
18 yrs old

Fairfeld et al.,
2001

Roubenoff and
Wilson, 2001

Sattler et al.,
1999 and
Sattler et al.,
2002

Total 30:
Nandrolone (n 5 15)
Nandrolone 1 exercise
(n 5 15)

Total 25:
Females (n 5 5)
Males w/wasting
(n 5 6)
Males and females
w/o wasting (n 5 19)

Total 43:
Placebo (n 5 12)
Testosterone (n 5 10)
Placebo 1 training
(n 5 10)
Testosterone 1
training (n 5 11)

3 sets of 8 repetitions at 80% 1-RM
for 12 weeks at 3 times per week

3 times per week for 12 weeks, 30
minutes on stationary bicycle at
60–70% age predicted max HR,
week 1 & 2, 2 sets 6–8 repetitions
at 60% 1 RM, week 3–6, 2 sets 6–8
repetitions at 70%, week 7–9, 2 sets
6–8 repetitions at 70% and 1 set
80%, week 10–12, 3 sets 6–8
repetitions at 80%
3 times per week for 8 weeks,
performed 3 sets of 8 repetitions at
80% 1-RM

(continued)

Significant increase (p , 0.0001) in
strength for wasting group (60%)
and nonwasting group (44%)
Significant, 2.3% increase in LBM in
nonwasted group, wasted group
had 5.3% improvement
Significant (p , 0.05 improvement on
the physical functioning subscale
of the SF-36 in wasted group
Significant increase (p , 0.03) in LDL
particle size in nandrolone with
exercise group
Significant increase (p , 0.001) HDL
cholesterol and decrease in fasting
triglycerides (p , 0.01) in the total
population
Nandrolone only group had a
significant increase in body weight
(3.2 6 2.7 kg) and lean body mass
(3.9 6 2.3 kg)
Exercise group had significant
increases in body weight (4.0 6 2.0
kg), LBM (5.2 6 5.7 kg), and
significant decrease in fat mass (1.2
6 1.3 kg)
Significant (p , 0.001) increases in
total thigh, quadriceps, and
hamstring muscle volume

Significant increase in thigh muscle
area and attenuation with
testosterone and training

EXERCISE AND HIV
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Males and females

Subjects

OF

48 total:
Females (n 5 8)
Exercise (n 5 18)
Control (n 5 30)

Number

PHYSIOLOGIC EFFECTS
IN

Intervention

Results
Exercise group significantly reduced
BMI (p , 0.04), decreased body
weight by an average of 1 kg more
than the control group
Significant reduction of the triceps
skinfold (p , 0.01), the peripheral
skinfolds (p , 0.02), the sum of
central skinfolds (p , 0.02), and
reduction of abdominal girth (p ,
0.02).
VO 2max increased in the exercise
group by 1.6 mL/kg more than
control group

HIV-INFECTION POPULATIONS (CONT’D )

Aerobic exercise 3 times a week, for
30 minutes a session for 12 weeks

EXERCISE INTERVENTIONS

HR, heart rate; RM, repetition maximum; LBM, lean body mass; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass index.

Smith et al.,
2001

Author

TABLE 2.
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Males and females,
27–45 yrs old

Males

Males and females

Stringer et al.,
1998

Wagner et al.,
1998

Neidig et al.,
2003

OF

IN

Exercised an average of 3.4 days per
week, for an average of 87 minutes,
at an average intensity of 6.1 of 8
See as Smith et al., 2001

6 weeks of training on stationary
bicycle at an increasing work rate
from 15–25 W/min until
exhaustion, with time adjusted so
each group produced the same
work, 3 times per week

45-minutes of aerobic exercise on a
stationary bicycle at 80% age
predicted max HR

Results

Significant (p , 0.000) improvements
on HAM-D, BSI-total, BSIdepression, Q-LES-Q
Improvement (p 5 0.03) in CES-D
scores, POMS (p 5 0.01), and
depression/rejection subscale
(p 5 0.05)

Exercise group had lower anxiety
(12.8 6 2.0 vs. 12.9 6 2.5) and
significantly lower depression (14.0
6 3.7 vs. 10.9 6 1.7) scores on the
POMS
Significant (p , 0.01) improvement in
quality of life, hope, and desire to
continue living did in both exercise
groups

HIV-INFECTION POPULATIONS

Intervention

EXERCISE INTERVENTIONS

Total 26:
Females (n 5 3)
Control (n 5 8),
Moderate exercise
(n 5 9)
Heavy exercise
(n 5 9)
Total 29:
Resistance (n 5 10)
Cardiovascular (n 5 2)
Total 48:
Females (n 5 3)
Exercise (n 5 18)
Control (n 5 30)

Total 23:
Exercise (n 5 10)
Control (n 5 13)

Number

PSYCHOLOGICAL EFFECTS

POMS, Profile of Mood States; HAM-D, Hamilton Depression Scale; BSI-total, Brief Symptom Inventory-distress, depression, anxiety; BSI-depression, Brief Symptom Inventory depression; Q-LES-Q, Endicott Quality of Life Enjoyment and Satisfaction Questionnaire; CES-D, Centers for Epidemiological Studies—Depression
Scale.

Males

Subjects

LaPerriere et al.,
1990

Author

TABLE 3.
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90

High-intensity exercise, which was shown to
decrease the effectiveness of the immune system for up to 21-hours in a non-HIV–infected
population in one study,68 was previously
avoided and moderate-intensity exercise was
prescribed. However, Terry et al.69 later found
that high-intensity exercise in an HIV-infected
person may not be detrimental to the immune
system based on data that showed no difference in CD41 and CD81 cell counts after 12
weeks between groups that exercised at 80%
maximum rate and 60% maximum heart rate.
Immunologic, physiologic, and psychological
effects of aerobic exercise in HIV-infected samples
For these reasons, aerobic training has been
used in many different forms as an intervention for HIV-infected persons. LaPerriere and
colleagues70 used an interval training method
on a cycle ergometer to examine changes in
lymphocyte cell counts in 16 men who began
exercising prior to undergoing HIV screening.
Patients worked at 70%–80% maximum heart
rate for 3 minutes followed by 2-minute sessions at a lower intensity. Findings showed that
45 minutes of training 3 times per week for 5
weeks significantly increased CD41 helper cell
counts (904 vs. 1020 mm3) and the CD81-inducer subset CD45RA1CD41 (no quantification
given) in those who presented as HIV positive.
LaPerriere and coworkers 71 also exercised
HIV-infected males, 18–40 years of age, on cycle ergometers 3 times per week for 45 minutes
per session at 70%–80% maximum age-predicted heart rate for 10 weeks. After comparing
preexercise to postexercise blood lymphocyte
levels, a significant increase was observed in
CD21 (1717 vs. 2183 mm3), CD41 (942 vs. 1280
mm3), CD81 (655 vs. 816 mm3), CD45RA1CD41
(312 vs. 955 mm3), and CD201 (162 vs. 244
mm 3) cell counts. These studies by LaPerriere
and associates71 are unique in that they are the
only two to show an actual increase in lymphocyte populations. Other studies have
shown that exercise does not decrease lymphocyte numbers,5,48,52 as well as showing that
exercise may attenuate the decrease in lymphocytes that occurs with normal disease progression, 51 but none have shown an increase in
cell numbers. This observed increase might ac-
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tually be the measurement of the mobilization
of cells from the lymphoid tissue, rather than
an actual increase in cell quantity.
Mustafa and colleagues 72 also addressed
CD41 cell counts while performing a longitudinal study on 415 homosexual males (156
HIV-infected [CD41 count 555 1 304] and 259
HIV-negative [988 1 380] at the time of enrollment) from 1985–1991 aimed at examining the
association between exercise and HIV disease
progression. Of the 156 HIV-infected men sampled, 68 progressed to AIDS, and 49 died of
AIDS-related complications. Individuals were
asked how many times per week they exercised, with an answer of 3–4 times per week being considered the minimum for inclusion in
the exercise group and those who exercised less
considered nonexercisers. Using a linear combination of parameter estimates, it was found
that exercise slowed progression to AIDS and
time to death with AIDS. Simple linear regression using CD41 cell counts as the dependent
variable, showed that CD4 counts increased 1
year, and had a lesser decline in other years
compared to the nonexercising group.
MacArthur and colleagues 73 evaluated various immunologic and cardiovascular parameters of 25 HIV-infected persons (24 males and
1 female), currently on antiretroviral therapy,
following a 24-week exercise program. Subjects
who exercised at 50%–60% VO 2max in four 10minute intervals comprised the low-intensity
group, and a high-intensity group worked at
75%–85% VO 2max for six 4-minute intervals.
Both groups performed exercise 3 times per
week on a treadmill, stationary bicycle, rower,
or stair-stepper. The 6 individuals who completed the program, 3 in each group, showed
no significant change in CD41 cell counts at
week 24 (185 vs. 195 cells per microliter), however, significant improvements were seen in
VO 2max (33.2 1 3.3 vs. 41.2 1 4.9 mL/kg per
minute), submaximal heart rate (137 1 8 vs.
124 1 7 beats per minute), and Relative Perceived Effort (RPE) (12.2 1 2.4 vs. 8.5 1 1.4). Individual group data were not analyzed because
of small number of subjects who completed the
intervention resulted in low power to detect
group differences.
Aerobic exercise interventions have also
been designed to evaluate changes in body
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composition and fatigue indices. Smith et al.74
implemented a regimen of 30-minute exercise
sessions 3 times per week for 12 weeks for 60
HIV-infected individuals (52 males and 8
females). Workloads were set at 60%–80%
VO 2max and were increased as needed to keep
the subject’s heart rates within set parameters.
Forty-nine subjects (75% taking antiretrovirals)
completed the program and showed a 1-minute
increase in time to fatigue on a treadmill (a
measure of physical endurance). Subjects in the
exercise group significantly reduced body mass
index (p , 0.04) and decreased body weight by
an average of 1 kg more than the control group
(1.5 kg lost vs. 0.5 kg lost). Included in the loss
of body weight was a significant reduction of
the triceps skinfold (p , 0.01), the peripheral
skinfolds (p , 0.02), and the sum of central
skinfolds (p , 0.02), as well as a reduction of
abdominal girth (p , 0.02). VO 2max increased in
the experimental group by 2.6 mL/kg compared to a 1 mL/kg increase in the control
group.
Terry et al.69 divided aerobically exercising
groups into a moderate intensity group who
worked at 60% maximal heart rate (n 5 11) and
high intensity group who exercised at 84%
maximal heart rate (n 5 10). Subjects were seen
3 times per week, and each session lasted approximately 1 hour with the first 15 minutes
and the last 15 minutes devoted to stretching
and the remaining 30 minutes consisting of
treadmill exercise at the prescribed intensity.
At the completion of the 12-week study, functional capacity, as measured by time to fatigue
on a maximal exercise test, increased in both
groups but more so in the high intensity group
(680 1 81 vs. 750 1 151 seconds for the moderate-intensity group and 651 1 122 vs. 841 1
158 seconds for the high-intensity group),
while no changes in body fat were observed.
Immunologic variables such as CD41 cells (592
vs. 614 vs. 683 mm3), CD81 cells (1030 vs. 1242
vs. 1252 mm 3), leukocytes (6344 vs. 6400 vs.
6930 mm3) and lymphocytes (2148 vs. 2627 vs.
2638 mm3 ) increased at 6 and 12 weeks, respectively, but were not statistically significant.
Depression scores, as obtained with the Montgomery-Asberg scale for depression, remained
unchanged from preintervention to postintervention. These results, however, lack authority
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because of low statistical power to detect
changes.
Aerobic exercise has also been linked to improvements in the psychological health of HIVinfected persons. Stringer and others5 evaluated immune indices and quality-of-life scores
before and after a 6-week exercise program.
Twenty-six HIV-infected individuals, 24 of
whom were on antiretroviral therapy, were divided into a control group (n 5 8), a moderateintensity exercise group (n 5 9), and a high-intensity exercise group (n 5 9). Aerobic training,
consisting of 6 weeks of 3 sessions per week on
a stationary bicycle, was prescribed with the
moderate-intensity group working approximately 60 minutes per session and the high-intensity group working less time, approximately
30–40 minutes, to produce equal work. Results
showed no significant change in CD41 count
(moderate, 297 vs. 310 mm3, heavy, 342 vs. 339
mm3) or viral load (moderate, 56,101 vs. 45,698/
mL; heavy: 11,706 vs. 10,326/mL) in any group,
but quality of life scores in the areas of quality
of life, hope, and desire to continue living did
significantly (p , 0.01) improve in both exercise groups.
LaPerriere and colleagues75 recruited 50 homosexual males unaware of their HIV status to
exercise prior to learning their HIV status. Exercise was performed on a cycle ergometer for
45 minutes, with 3-minute stages at 80% age
predicted maximum heart rate alternated with
2-minute stages at 60%–79% predicted maximal heart rate. Based on results from the Profile of Mood States and the State-Trait Anxiety
Inventory, the 10 men in the exercise group
who were diagnosed HIV positive had lower
anxiety (12.8 1 2.0 vs. 12.9 1 2.5) and depression (14.0 1 3.7 vs. 10.9 1 1.7) scores than did
those HIV-positive men who did not exercise.
Nonexercisers also had a decrease in CD41 cell
number (61 cells/mm 3) that was blunted in the
exercise group (increase of 38 cells/mm3).
The effects of aerobic exercise on depression
in HIV-infected individuals were studied by
Neidig and colleagues.76 The 49 subjects who
completed the previously mentioned study by
Smith et al. were also given tests to determine
depression levels using the Center for Epidemiological Studies-Depression Scale (CESD), the Beck Depression Inventory (BDI), Pro-
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file of Mood States (POMS), and stress was assessed with the Perceived Stress Scale 4 (PSS4). Those who completed the exercise intervention showed significant improvement in
CES-D scores (p 5 0.03), the 65-item POMS
(p 5 0.01), and on the depression/rejection
subscale (p 5 0.05).
Physiologic effects of resistance training in
HIV-infected samples
To assess the ability of the HIV-infected person to adapt to load, Roubenoff and coworkers77 prescribed an 8-week regimen of 3 weekly
sessions consisting of resistance training with 3
sets of 8 repetitions performed at 80% of the
subjects’ 1-RM. The men (n 5 20) and women
(n 5 5), all of whom were taking antiretroviral
therapy, rated the difficulty of each exercise set
on the Borg RPE Scale, and resistance was increased the following session if the RPE was less
than 16. At the conclusion of the 8-week intervention, there was a significant (p , 0.0002) increase in lean body mass (1.75 1 1.94 kg), and
strength (as tested by 1-RM) on the chest press
(31 1 18%), leg press (40 1 23.6%), upper back
(50 1 27%), and quadriceps extension (38 1
31%). There was also a significant (p , 0.05) decrease in fat mass (0.92 1 2.22 kg), while overall body weight remained the same.
Roubenoff and Wilson1 next compared the
effects of progressive resistance training (PRT)
on physical functioning in wasted (n 5 6) and
nonwasted (n 5 19) HIV-infected populations.
The wasted group was classified by involuntary weight loss of greater than 10% baseline
body weight, fewer documented for more than
30 days, chronic weakness, and/or chronic diarrhea independent of any conditions other
than HIV-infected that may lead to weight
loss.78 Three subjects with wasting were on antiretroviral therapy and 10 nonwasted subjects
were on antiretroviral therapy. The training
regimen was consistent with the previous
study (3 sessions per week for 8 weeks, with
subjects performing 3 sets of 8 repetitions at
80% 1-RM on the chest press, leg press, leg extension, and upper back machines). A significant increase (p , 0.0001) in strength, assessed
by average 1-RM on four machines, was observed in the wasting group (60% increase) and
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the nonwasting group (44% increase). A significant, 2.3% increase in lean body mass (LBM)
was observed in the nonwasted group, while
the wasted group exhibited at 5.3% improvement. Wasted subjects also had a significant
(p , 0.05) 6-point improvement on the physical functioning subscale of the Medical Outcomes Study (MOS) Short Form 36 (SF-36)
questionnaire.
The effects of resistance exercise, along with
whey protein supplementation, was tested in
30 HIV-infected women by Agin et al.79 Subjects were divided into a protein only group
(n 5 10), an exercise only group (n 5 10), and
a combined therapy group (n 5 10). After a 6week control period, 14 weeks of resistance
training was implemented. Results showed no
significant changes in strength or quality of life
(QOL) during the control period. Protein only
patients gained 3.6 kg (p 5 0.001), and 2.5 kg
of fat (p 5 0.002), with no change in skeletal
muscle mass (0.6 kg; p 5 0.12). The exercise-only
group increased skeletal muscle mass (1.2 kg;
p , 0.001) and decreased fat mass (1.7 kg; p 5
0.02). The combined therapy group had no
change in skeletal muscle (0.6 kg; p 5 0.30).
Strength increased for both exercise groups (40.6
to 95.3%; p , 0.001). The QOL physical activity
score improved for the exercise group (p 5 0.02)
and worsened for protein group (p 5 0.01).
Physiologic effects of combined aerobic and
resistance training in HIV-infected samples
The combination of aerobic and resistance
training has been used to treat HIV-infected
persons. Rigsby and colleagues80 subjected 16
patients to a 12-week exercise program consisting of 3 visits per week, and 15 patients attended 1.5 to 2 hour counseling sessions at least
1 time per week during the same 12-week period. Subjects in the exercise group performed
20 minutes of aerobic exercise on a stationary
bicycle at 60%–80% maximum heart rate followed by 35 minutes of combined strength and
flexibility exercises. Strength training was conducted on a hydraulic isokinetic weight-training machine and 3 sets were limited to no more
than 30 repetitions total. The results showed
that subjects in the exercise group significantly
improved muscular strength in the chest press
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(189.39 1 25.58 vs. 239.66 1 33.24 n?m newtonmeter) and the leg extension (158.74 1 43.43 vs.
206.28 1 43.06 Newton-meter (n?m) while also
improving cardiorespiratory fitness, as measured by total time completed during the cycle
test (996.15 1 170.43 vs. 1388.46 1 224.45 seconds), but no improvements were seen in the
counseling group. Measurement of immune
markers showed no significant effect of either
counseling or exercise on total leukocytes, total lymphocytes, CD41, or CD81 cell counts.
Physiologic effects of exercise and
anabolic supplementation
It has become common practice to combine
progressive resistance training and anabolic
supplementation when treating AIDS patients.
These treatments are effective in increasing
body weight, but they have been shown to
cause liver toxicity and elevated serum lipid
levels, thus strict monitoring is required.81
Grinspoon and colleagues82 showed that greater
increases in LBM occurred when combining
testosterone and exercise as compared to testosterone treatment alone. Subjects with AIDS
wasting were divided into four study groups:
placebo with no exercise (n 5 12), placebo with
exercise (n 5 10), testosterone with no exercise
(n 5 10), testosterone with exercise (n 5 11).
Participants placed in the testosterone groups
received intramuscular testosterone enanthate
injections (200 mg/wk) for the 12-week duration
of the study. The exercise groups trained 3 times
per week, beginning each session with 20 minutes of aerobic exercise followed by resistance
training. Resistance training involved 6 exercises
(3 lower body and 3 upper body). Training was
conducted as follows: weeks 1 and 2, 2 sets of 8
repetitions at 60% 1-RM; weeks 3 through 6, 2
sets of 8 repetitions at 70% 1-RM; weeks 7
through 12, 3 sets of 8 repetitions at 80% 1-RM.
LBM significantly increased with training, independent of testosterone (2.3 kg), and with testosterone an increase of 4.2 kg increase was observed. Isometric strength testing showed no
effect of training or testosterone, but trained subjects did double their training volume.
Bhasin and others83 showed that testosterone
and exercise independently increased LBM and
muscular strength in 16 weeks, although no ad-
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ditive effect was observed. Forty-nine HIV-infected males, 18–50 years of age with low
serum testosterone levels and a 5% or greater
weight loss in the previous 6 months completed
the study. Subjects in the exercise groups
trained 3 times per week at 60% of their 1-RM
for 3 sets of 12–15 repetitions for the first 4
weeks. Weeks 5–10 consisted of 4 sets of 4–6
repetitions, with a 90% 1-RM intensity on
heavy days, 80% 1-RM on medium days, and
70% 1-RM on light days. A similar pattern was
followed for the remaining weeks, with upper
body exercise resistance being increased by 7%
and lower body resistance by 12%. Subjects in
the exercise alone group showed a 29%–36% increase in strength, while the testosterone only
group showed a 17%–28% increase, but there
was no additive effect of the two therapies combined. Thigh muscle volume increased by 40
cm3 (p , 0.001) in the testosterone-only group,
by 62 cm3 (p , 0.003) in the exercise-only
group, and volume increased by 44 cm3 (p ,
0.001) in the combined therapy group. Body
weight significantly increased in the testosterone only group (p , 0.001), but did not
change in the other two groups receiving therapy. There was no additive effect of the two
therapies on LBM, however, both the testosterone-only (p , 0.05) and exercise-only (p ,
0.04) increased significantly.
Sattler and others84 had 14 subjects perform
3 sets of 8 repetitions of resistance exercise at
80% 1-RM, while simultaneously treating them
with a 200-mg injection of nandrolone decanoate (anabolic steroid) during week 1, 400
mg for week 2, and 600 mg for the remainder
of the exercise intervention; 14 other subjects
received only the nandrolone deconoate. After
12 weeks, the nandrolone-only group had a significant increase in body weight (3.2 1 2.7 kg)
and lean body mass (3.9 1 2.3 kg), but no significant change in body fat. The exercise group
also had significant increases in body weight
(4.0 1 2.0 kg) and lean body mass (5.2 1 5.7
kg), which were greater than those observed in
the steroid only group, as well as a significant
decrease in fat mass (1.2 1 1.3 kg). Both groups
also showed significant (p , 0.001) increases in
total thigh, quadriceps, and hamstring muscle
area.
Wagner et al.85 recruited 54 men to partici-
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pate in biweekly treatments of testosterone at
200 mg during weeks 1 and 2, and 400 mg during weeks 3–8. Prior to the intervention, and
again at week 12, psychiatrists administered the
Structural Clinical Inventory (used to diagnose
mood disorders), the Hamilton Rating Scale for
Depression (HAM-D), the Brief Symptom Inventory (measures distress [BSI-total], anxiety
[BSI-anxiety], and depression [BSI-depression]),
and the Endicott Quality of Life Enjoyment and
Satisfaction Questionnaire (Q-LES-Q). Additionally, total body weight, lean body mass, and
body fat were measured by bioelectrical impedance at week 0 and week 12. Twenty-nine
men reported engaging in exercise during the
study, with 10 reporting only resistance exercise and 2 reporting only cardiovascular exercise. These men reported exercising an average
of 3.4 days per week, for an average of 87 minutes, at an average intensity of 6.1 of 8, with 8
being the most intense. Exercisers showed significant (p , 0.000) improvements in each of the
psychological evaluations, while nonexercisers
showed a significant (p , 0.000) improvement
in only the HAM-D. The nonexercisers exhibited no changes in body composition, while the
exercisers had a significant (p , 0.000) improvement in lean body mass (61.6 1 7.2 vs.
64.2 1 8.2 kg).
In addition to skeletal muscle adaptations
and changes in fat mass, exercise and testosterone used in combination can cause other
metabolic changes. Using the exercise and nandrolone deconoate treatment schedule as previously discussed,75 Sattler et al.86 evaluated
the effects of nandrolone on various risk factors of cardiovascular disease. Measurement at
week 12 showed a significant increase (p ,
0.03) in low-density lipoprotein (LDL) particle
size in the nandrolone and exercise group, as
well as in total high-density lipoprotein (HDL)
cholesterol in the total population (p , 0.001).
The LDL changes returned to no significance at
week 24, while the total HDL remained significantly higher (p , 0.01) in the exercise-group
only. Fasting triglycerides were significantly
reduced (p , 0.01) in the total population at
week 12, but this was not sustained throughout the 24-week study. These results do not allow for a definitive statement as to the efficacy
of anabolic therapy in HIV-infected persons in
terms of cardiovascular disease risk factors.
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Forty-three HIV-infected men with AIDS
wasting syndrome were recruited by Fairfield
et al.87 to participate in this study. The men were
randomly assigned to the following groups:
placebo with no training (n 5 12), testosterone
(200 mg/wk) with no training (n 5 10), placebo
with training (n 5 10), and testosterone (200
mg/wk) with training (n 5 11). The exercise
protocol consisted of 3 sessions per week for 12
weeks. Each workout consisted of 30 minutes
on a stationary bicycle at 60%–70% the subjects
age predicted maximum heart rate. The resistance exercise for weeks 1 and 2 included 2 sets
of 6–8 repetitions at 60% 1-RM; weeks 3 to 6, 2
sets of 6–8 repetitions at 70%; weeks 7 to 9, 2
sets of 6–8 repetitions at 70% and 1 sets 80%;
and weeks 10 to 12, 3 sets of 6–8 repetitions at
80%. Both testosterone therapy and exercise
were found to increase thigh muscle attenuation, while the combination proved to elicit the
greatest increase (no data).
No research that examines the effects of
lower intensity resistance exercise in HIV-infected populations has been found. The physiologic benefits of resistance training can be attained at intensities below 80% 1-RM, yet
investigators have failed to examine this type
of training. The rationale for using 80% 1-RM
for a resistance training protocol is not described by the researchers, but may stem from
recommendations by agencies such as the
ACSM, which state that resistance exercise
above 80% 1-RM is beneficial for rapid gains in
strength. 37 The ACSM manual goes on to say
that resistance exercise at 40%–60% 1-RM is
sufficient for the development of strength,
again begging the question as to why this intensity of training has not been tested. 37

DISCUSSION
More attention is needed to determine the
type, duration, frequency, and intensity of exercise needed to elicit physiologic and psychological changes in the HIV-infected population.
It is evident that no distinct connection has
been made between exercise duration and intensity on CD41 cell counts,5,48–52 leaving more
research to be done regarding exercise and immune indices in the HIV-infected person. These
cell counts can differ by compartment and time
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after exercise, so researchers need to be consistent in retrieving data so true comparisons can
be made. Furthermore, mixed results have been
obtained regarding aerobic exercise prescription and psychological evaluations.5,54,55 Studies of this nature should include a control
group that attends some form of therapy for
the same amount of time the exercise group is
in contact with the research team. Additionally,
with prevalence rates as high as 28%,19 some
consideration should be given to examining the
effects of exercise in the HIV-infected anemic.
Inflammatory and repair mechanisms of the
trained muscle of HIV-infected persons have
yet to be fully documented. Changes in inflammatory cytokines (IL-1, IL-6, TNF-a) with HIVinfection, as well as the presence of chronic
inflammatory markers caused by chronic infection, may alter the healing process, and consequently, the adaptive ability of muscle to stress.
Muscle biopsy would provide invaluable insight into these, and many other questions surrounding muscle in an HIV-infected host.
Finally, a major problem with a number of
these studies is low statistical power and major threats to internal validity. The problems
can be attributed to differential attrition, with
nonequivalent treatment and control groups.
Validity of the control groups is also compromised by not having the same amount of personal interaction between treatment and control groups. Error is also present when using
heart rate as a measure of work rate because
cardiac neuropathy is common to many HIVinfected persons. All study designs should include a nutritional assessment to rule diet out
as a confounding variable. Improvement in
study design would allow for better comparisons between studies, and may help to explain
discrepancies that exist among them, particularly in terms of impact on CD41 cells.
Study sample characteristics also limit the
generalizability of many of these studies. Many
studies have been done only using males, leaving the effects of exercise on females relatively
unknown.

CONCLUSION
Current research shows that high- and moderate-intensity aerobic training and resistance

training implemented by trained professionals
are both safe and effective in HIV-infected persons. The intervention studies reviewed in this
paper have shown the ability to increase muscular strength and endurance, improve body
composition, and improve mood while not adversely compromising the immune system. For
persons suffering from symptoms, exhaustive
exercise should be avoided, but activity of
moderate intensity is still encouraged. It should
be noted that all HIV-infected individuals and
their trainers should be in constant contact with
the patient’s physician regarding progress and
changes in health and performance levels. Programs should be designed in accordance with
the ACSM guidelines for exercise testing and
prescription, and careful attention should be
given to avoid overtraining.
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